Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review (Q38693748)

5 September 2017

title

Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review (English)

1 reference

5 September 2017

1 reference

1 reference

Scott C Howard

1

1 reference

5 September 2017

Steven Trifilio

2

1 reference

5 September 2017

Tara K Gregory

3

1 reference

5 September 2017

Nadine Baxter

4

1 reference

5 September 2017

Ali McBride

5

1 reference

5 September 2017

language of work or name

1 reference

12 January 2016

1 reference

5 September 2017

1 reference

5 September 2017

volume

95

1 reference

5 September 2017

issue

4

1 reference

5 September 2017

page(s)

563-573

1 reference

A review of tumour lysis syndrome with targeted therapies and the role of rasburicase

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2585-7

21 January 2018

The tumor lysis syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2585-7

Tumor lysis syndrome: new challenges and recent advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2585-7

Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2585-7

An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2585-7

Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2585-7

Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2585-7

Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2585-7

Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2585-7

Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2585-7

A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2585-7

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2585-7

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2585-7

An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2585-7

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2585-7

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2585-7

Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2585-7

Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2585-7

A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2585-7

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2585-7

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2585-7

Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2585-7

A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2585-7

Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2585-7

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2585-7

Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2585-7

Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2585-7

Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2585-7

A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2585-7

A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2585-7

Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2585-7

Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2585-7

Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2585-7

A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2585-7

Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2585-7

A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2585-7

10.1007/S00277-015-2585-7

21 January 2018

Identifiers

DOI

1 reference

5 September 2017

1 reference